AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib

ZiJie Liu; Xia Wu; Yong Duan; YuMing Wang; Bin Shan; JinXing Kong; XiaoBo Ma; YuXia Bao

doi:10.1016/j.leukres.2011.04.020

AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib

Leuk Res. 2011 Oct;35(10):1355-9. doi: 10.1016/j.leukres.2011.04.020. Epub 2011 May 13.

Authors

ZiJie Liu¹, Xia Wu, Yong Duan, YuMing Wang, Bin Shan, JinXing Kong, XiaoBo Ma, YuXia Bao

Affiliation

¹ Department of Laboratory Medicine, The First Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, China.

PMID: 21570118
DOI: 10.1016/j.leukres.2011.04.020

Abstract

Activation-induced deaminase (AID), a cytidine deaminase, can accelerate the acquisition of BCR-ABL1 kinase domain mutations in human CML. In the present study, we investigated the expression of AID and Bcr-Abl in CML cells derived from 35 clinical patients. We found that both AID and Bcr-Abl were correlatively over-expressed in CML-LBC (lymphoid blast crisis) cells as compared with those in CML-CP (chronic phase) cells. AID expression was significantly decreased in CML-LBC cells after treated with arsenic trioxide, especially together with imatinib. We also observed satisfied therapy effects of As(2)O(3) and imatinib on patients with CML blast crisis. These data suggest that decreasing AID expression in CML-LBC by As(2)O(3) may be a promising approach to CML treatment.

MeSH terms

Adult
Antineoplastic Agents / pharmacology*
Arsenic Trioxide
Arsenicals / pharmacology
Benzamides
Blast Crisis / drug therapy*
Blast Crisis / genetics*
Blast Crisis / metabolism
Blast Crisis / pathology
Blotting, Western
Cells, Cultured
Cytidine Deaminase / genetics*
Cytidine Deaminase / metabolism
Down-Regulation / drug effects
Drug Resistance, Neoplasm / drug effects
Drug Synergism
Female
Fusion Proteins, bcr-abl / genetics*
Fusion Proteins, bcr-abl / metabolism
Gene Expression / drug effects
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Leukocytes, Mononuclear / metabolism*
Leukocytes, Mononuclear / pathology
Male
Middle Aged
Mutation
Oxides / pharmacology
Piperazines / pharmacology
Pyrimidines / pharmacology
Reverse Transcriptase Polymerase Chain Reaction

Substances

Antineoplastic Agents
Arsenicals
Benzamides
Oxides
Piperazines
Pyrimidines
Imatinib Mesylate
Fusion Proteins, bcr-abl
AICDA (activation-induced cytidine deaminase)
Cytidine Deaminase
Arsenic Trioxide